<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771442</url>
  </required_header>
  <id_info>
    <org_study_id>2020-SVS</org_study_id>
    <nct_id>NCT04771442</nct_id>
  </id_info>
  <brief_title>Stem Cell Treatment of Peyronie´s Disease.</brief_title>
  <official_title>Treatment With Stromal Vascular Fraction of Peyronie´s Disease in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital of South West Jutland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital of South West Jutland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the project is to investigate if a single injection of autologous stromal vascular&#xD;
      fraction into and around plaque is a safe and suitable treatment.&#xD;
&#xD;
      Twentythree men &gt; 18 years with Peyronie´s Disease in the chronic phase will be recruited.&#xD;
&#xD;
      The operative same-day procedure will be performed in general anaesthesia by a plastic&#xD;
      surgeon. Before the patient wake, local anaesthesia is put around the penis. Processed stem&#xD;
      cells are injected into the plaque/fibrosis subcutaneously.&#xD;
&#xD;
      There will be a follow up at 1, 3, 6, 12 months. It is a pilot study with no randomisation.&#xD;
      The group will be compared to a historical control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the bend of the erect penis</measure>
    <time_frame>[measured at baseline, 1, 3, 6, 12 months]</time_frame>
    <description>Changes in degrees measured with a goniometer compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Peyronie´s disease questionnaire bother symptoms</measure>
    <time_frame>[measured at baseline, 1, 3, 6, 12 months]</time_frame>
    <description>Will there be less bother symptoms compared to baseline? Score 0-44. The higher the score the more symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Index of Erectile Function score,</measure>
    <time_frame>[measured at baseline, 1, 3, 6, 12 months].</time_frame>
    <description>Score can be 5-25, the higher the score the less symptoms. Answers are compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stretched Penile Length from symphysis to meatus of the glans (cm)</measure>
    <time_frame>[measured at baseline, 1, and 12 months]</time_frame>
    <description>Ruler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in penile Plaque size (mm3)</measure>
    <time_frame>[measured at baseline, 1, and 12 months]</time_frame>
    <description>Ultrasonic scanner</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Penile Induration</condition>
  <condition>Penile Diseases</condition>
  <arm_group>
    <arm_group_label>Stromal vascular fraction injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:&#xD;
Single injection with autologous adipose tissue-derived stromal vascular fraction cells in and around the plaque.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stromal vascular fraction</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Stromal vascular fraction injection</arm_group_label>
    <other_name>SVF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acquired penile curvature &gt;30 and &lt;90 degrees associated with a palpable penile plaque&#xD;
             on physical examination.&#xD;
&#xD;
          2. One or several plaques at ultrasound screening.&#xD;
&#xD;
          3. Willingness to attend follow-up at 1, 3, 6 and 12 months.&#xD;
&#xD;
          4. Understand and speak Danish.&#xD;
&#xD;
          5. Men &gt; 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients may not be:&#xD;
&#xD;
          1. Taking the medication Coumadin, Warfarin or NOAK (new oral anticoagulant).&#xD;
&#xD;
          2. Unable to achieve adequate erection with penile injection to access degree of&#xD;
             curvature.&#xD;
&#xD;
          3. Undergoing definitive treatment for prostate cancer, bladder cancer, or other pelvic&#xD;
             malignancies including surgery, external beam radiation therapy, brachytherapy, and&#xD;
             cryotherapy.&#xD;
&#xD;
          4. With prior history of prostate cancer, hematologic disorders, chronic liver disease&#xD;
             including cirrhosis and hepatitis C, disorders affecting the immune system, including&#xD;
             infection with the human immunodeficiency virus, or psychiatric disorders including&#xD;
             but not limited to major depression, schizophrenia, bipolar disease.&#xD;
&#xD;
          5. With a history of cerebrovascular incidents, a history of deep venous thrombosis&#xD;
             within the past 5 years or a history of untreated or severe sleep apnoea.&#xD;
&#xD;
          6. With a clinically significant abnormal, results that would put the subject at&#xD;
             increased risk or compromise the integrity of the study data, in the opinion of the&#xD;
             investigator. Blood tests will be analysed for HIV, Hepatitis B and C and syphilis and&#xD;
             those applicable within guidelines of the department.&#xD;
&#xD;
          7. Involved with any other projects with an investigational drug within 30 days.&#xD;
&#xD;
          8. In treatment for alcohol or drug abuse within six months.&#xD;
&#xD;
          9. With congenital deviation of penis.&#xD;
&#xD;
         10. Within six months treated with Collagenase, ESWT and/or other therapeutic injection in&#xD;
             the plaque treatment for PD.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Majken Wiborg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital, Southwest Jytland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Majken H Wiborg, MD</last_name>
    <phone>+45 26 36 22 87</phone>
    <email>majken.hojrup.wiborg@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Lund, Professor</last_name>
    <phone>+45 51408982</phone>
    <email>lars.lund@rsyd.dk</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stromal vascular fraction</keyword>
  <keyword>Peyronie´s disease</keyword>
  <keyword>Peyronie´s disease questionnaire</keyword>
  <keyword>Erectile dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
    <mesh_term>Penile Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

